TAE684 (NVP-TAE684)

Catalog No.S1108

TAE684 (NVP-TAE684) Chemical Structure

Molecular Weight(MW): 614.2

TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.

Size Price Stock Quantity  
USD 160 In stock
USD 290 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) H3122 xenografts harboring the EML4-ALK translocation were treated with control vehicle or the ALK inhibitor, TAE-684, for 2 days; the tumors were excised and lysates were prepared. The TIMM results for the control and treated animals are shown. (B) H3122 cells were treated in the presence or absence of TAE-684 (100 nM) for 6 hours in the presence or absence of the indicated ligands [EGF (50 ng/mL), IGF1 (50 ng/mL), and HGF (50 ng/mL)]. Extracts were probed with the indicated antibodies.

    Cancer Res 2011 71, 4920-31. TAE684 (NVP-TAE684) purchased from Selleck.

    Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (B) Dosage effects of TAE684 on phospho-Y1604 ALK expression of wild-type, H694R, and E1384K transfectants by Western blot analysis (top panel). Quantitative results of phospho-Y1604 ALK intensity are also (bottom panel).

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

  • Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (C) Suppressive effects of TAE684 on H694R- and E1384K-induced tumors in vivo. Photographs and tumor growth curves are shown in the top and bottom panels, respectively (four mice per group).

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

    Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (A) Dosage effects of TAE684 on H694R- and E1384K-induced cell proliferation measured with WST-1 activity. 

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

Purity & Quality Control

Choose Selective ALK Inhibitors

Biological Activity

Description TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.
Targets
ALK [1]
(Cell-free assay)
3 nM
In vitro

TAE684 does not exhibit significant cross-reactivity against other kinases. TAE684 potently inhibits the proliferation of Ba/F3 NPM-ALK cells with IC50 of 3 nM, without affecting the survival of Ba/F3 cells even at 1 μM. TAE684 also inhibits proliferation of NPM-ALK-expressing human ALCL cell lines including Karpas-299 and SU-DHL-1 with IC50 of 2–5 nM. Molecular modeling reveals that L258 may be one of the major kinase-selectivity determinants for TAE684. TAE684 treatment results in a rapid and sustained inhibition of phosphorylation of NPM-ALK. TAE684 induces apoptosis and G1 phase arrest in NPM-ALK-expressing Ba/F3 cells and ALCL patient cell lines. [1] TAE684 markedly overcomes Crizotinib-resistance in H3122 CR cells, harboring the fusion oncogene EML4-ALK, decreasing cell growth, suppressing ALK phosphorylation and inducing apoptosis.[2] Neurite outgrowth induced by expression of the mALK R1279Q mutant could be completely inhibited by TAE684 at 30 nM. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwMECwNFYxOyEQvF2= M4\1PXNCVkeHUh?=
SF539 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVviWXRKUUN3ME2wMlAxODV4NDFOwG0> M1nPPHNCVkeHUh?=
DEL NYrO[mViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMECwPVI4KM7:TR?= MYXTRW5ITVJ?
NB1 M2Dv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzhcFJKSzVyPUCuNFAyPjJizszN MXrTRW5ITVJ?
SR NYr3dI9TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTGTWM2OD1yLkCwNlc4KM7:TR?= MX7TRW5ITVJ?
KARPAS-299 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLBXVFMUUN3ME2wMlAzOzh2IN88US=> M4f6XnNCVkeHUh?=
MHH-CALL-2 M37vc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXJOoFPUUN3ME2wMlAzQTV{IN88US=> MU\TRW5ITVJ?
SU-DHL-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMES4OlUh|ryP NILLN5lUSU6JRWK=
A4-Fuk NEHSSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorTTWM2OD1yLkC1OVY2KM7:TR?= M1T2W3NCVkeHUh?=
EW-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMUCyOVYh|ryP MmPHV2FPT0WU
NOS-1 NXvEVlVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLXTWM2OD1yLkGwNlk1KM7:TR?= MXjTRW5ITVJ?
EW-16 NHnmcHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMUC1Olgh|ryP NYnPPZh4W0GQR1XS
TE-11 NFjP[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S5SmlEPTB;MD6xOlA6PiEQvF2= NU\K[mtEW0GQR1XS
SW982 NVjaUpQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvUS2xQUUN3ME2wMlE3PDd6IN88US=> MWPTRW5ITVJ?
LAN-6 NY\1[3YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMUe0OFMh|ryP NXTEN5V1W0GQR1XS
MZ1-PC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTJTWM2OD1yLkG3PFM2KM7:TR?= MV\TRW5ITVJ?
KS-1 NFjVWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkGwTWM2OD1yLkG5N|Q{KM7:TR?= MW\TRW5ITVJ?
PSN1 M4TKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3RdIhOUUN3ME2wMlE6PjNzIN88US=> MkDPV2FPT0WU
LC-2-ad NHHQPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMUm2PVIh|ryP MWnTRW5ITVJ?
COLO-320-HSR MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkKyTWM2OD1yLkG5O|c3KM7:TR?= MXLTRW5ITVJ?
OPM-2 MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrCfWs3UUN3ME2wMlIzPjZ7IN88US=> M1PkUXNCVkeHUh?=
SK-NEP-1 MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL3Wo5KSzVyPUCuNlM2OjRizszN M1nxS3NCVkeHUh?=
ALL-PO NGDYXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMkS1NlQh|ryP Mm\OV2FPT0WU
CMK MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPjW25iUUN3ME2wMlI2PTNizszN M1HMSnNCVkeHUh?=
NCI-H1648 NIrxXWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jxeWlEPTB;MD6yO|g2PSEQvF2= M1TmOnNCVkeHUh?=
SIG-M5 NVjH[JFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LnUGlEPTB;MD6yPVE2QSEQvF2= MmGyV2FPT0WU
TGBC24TKB M2Pzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlmxTWM2OD1yLkOwNlE5KM7:TR?= MoPiV2FPT0WU
DOHH-2 NG\yb2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnGO5FKSzVyPUCuN|EzODRizszN NYqxfXpxW0GQR1XS
NB69 NGnZT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLXTWM2OD1yLkOxO|g4KM7:TR?= M2XHZnNCVkeHUh?=
MFH-ino NWC5XnJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwM{K1NlMh|ryP MXrTRW5ITVJ?
KP-N-RT-BM-1 NXnLSpFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwM{OxNlMh|ryP Mn[5V2FPT0WU
MONO-MAC-6 NXntRlZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwM{OyPVEh|ryP NV\NeIJpW0GQR1XS
ATN-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwM{OzNFMh|ryP MkjMV2FPT0WU
NTERA-S-cl-D1 MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLvTWM2OD1yLkOzN|k3KM7:TR?= MXPTRW5ITVJ?
L-540 NYDXWVlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NESzUmtKSzVyPUCuN|Y6QDhizszN NIfZRYNUSU6JRWK=
GB-1 MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwM{i4Olch|ryP M4q4d3NCVkeHUh?=
MV-4-11 NYPxZmRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NICwWpZKSzVyPUCuN|k1PDZizszN NGDGT3pUSU6JRWK=
KG-1 NVTQbFlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLvboVTUUN3ME2wMlM6PTZzIN88US=> MmDFV2FPT0WU
OVCAR-4 M1fWWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVK1c5psUUN3ME2wMlQxPTZ7IN88US=> M{TSZ3NCVkeHUh?=
NEC8 MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG5clBKSzVyPUCuOFEzQTJizszN NHfzN2dUSU6JRWK=
SK-MM-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDuUYlKSzVyPUCuOFE3ODlizszN M4G2fnNCVkeHUh?=
TE-8 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HVfWlEPTB;MD60Nlg5KM7:TR?= MkDXV2FPT0WU
697 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPndpZIUUN3ME2wMlQ{OjF3IN88US=> NViwTJRJW0GQR1XS
NB14 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3STWM2OD1yLkSzPFI3KM7:TR?= MkPKV2FPT0WU
GDM-1 NUfRUmR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTlTWM2OD1yLkS3NVE3KM7:TR?= NV7QbG9SW0GQR1XS
HUTU-80 NUfZW3R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HsUWlEPTB;MD60O|M4PSEQvF2= NYnVTll2W0GQR1XS
HL-60 M1\wVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTvbo1rUUN3ME2wMlQ5OTR{IN88US=> MlLCV2FPT0WU
OCI-AML2 NHLCNHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrrTWM2OD1yLkS4N|I5KM7:TR?= M3fjVnNCVkeHUh?=
ML-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHP[GhKSzVyPUCuOFkxOzFizszN Mkn0V2FPT0WU
ES4 NFnBTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFv4PHZKSzVyPUCuOFkyODlizszN M3WwRnNCVkeHUh?=
NCI-H747 M3LCfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\1elVJUUN3ME2wMlQ6QDlizszN NHr1RVZUSU6JRWK=
RL95-2 M2O0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvKTWM2OD1yLkWwNVEzKM7:TR?= MmjBV2FPT0WU
TE-15 M{HsUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NImwU49KSzVyPUCuOVEyOjRizszN NYLjb2JTW0GQR1XS
TE-12 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDYe4JKSzVyPUCuOVM{PDlizszN Mn;1V2FPT0WU
LB1047-RCC NX\pfXF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\zPWlEPTB;MD61OFU1QSEQvF2= M2HYUnNCVkeHUh?=
LB831-BLC MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\MZVNKSzVyPUCuOVUxOjNizszN Mn\UV2FPT0WU
NCI-H1355 MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLyTWM2OD1yLkW1NVg1KM7:TR?= Mle0V2FPT0WU
CTV-1 NHTDOoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHzdVRnUUN3ME2wMlU2PjJ2IN88US=> NEK5XVRUSU6JRWK=
RXF393 M173[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTPTWM2OD1yLkW1O|k1KM7:TR?= NE\MNXlUSU6JRWK=
SW872 NHjUSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\6TWM2OD1yLkW2O|I1KM7:TR?= NWXtXGF1W0GQR1XS
MPP-89 NX32[GdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDqT4lPUUN3ME2wMlU4QDh2IN88US=> MVfTRW5ITVJ?
RPMI-8226 NIrPVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7pUlloUUN3ME2wMlY{PTJ4IN88US=> M1P4SHNCVkeHUh?=
LS-1034 NF3tb|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDGSVBKSzVyPUCuOlM2QCEQvF2= MlvwV2FPT0WU
SJSA-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\uNoZlUUN3ME2wMlY{PzJ3IN88US=> NGDjO3VUSU6JRWK=
HOP-62 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjVbHpKSzVyPUCuOlUxOzNizszN NVnDS|RpW0GQR1XS
KGN MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nWV2lEPTB;MD62OlE3QCEQvF2= NXHweFR1W0GQR1XS
D-336MG NWXYZZp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfR[GJGUUN3ME2wMlY3OTZ7IN88US=> NUPIPFdRW0GQR1XS
LS-411N M1XkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\CUnpKSzVyPUCuOlc1PjJizszN NF;G[WZUSU6JRWK=
TE-1 M2fYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13zNWlEPTB;MD62PVA4PCEQvF2= NEmyd29USU6JRWK=
LB996-RCC NF;yRVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXMS2hKSzVyPUCuOlk{QDlizszN M37DS3NCVkeHUh?=
TE-10 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnyU5RHUUN3ME2wMlcyPDl4IN88US=> NG\6UIdUSU6JRWK=
NCI-SNU-16 M2\USGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml25TWM2OD1yLkeyOlY1KM7:TR?= Mo\5V2FPT0WU
ES8 MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlO4TWM2OD1yLke0PVc2KM7:TR?= MkDJV2FPT0WU
COLO-800 NFjzPVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O1TWlEPTB;MD63OlY6PSEQvF2= MWrTRW5ITVJ?
ES6 MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwN{e1OVkh|ryP NUCwb5h1W0GQR1XS
L-363 MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwOEKzO|Uh|ryP NFf1U2pUSU6JRWK=
NMC-G1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:zdmNKSzVyPUCuPFMzOzNizszN NGrie2xUSU6JRWK=
LU-134-A M37ORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\YbHZXUUN3ME2wMlg{QTF{IN88US=> MVPTRW5ITVJ?
SF268 M1zqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;LTWM2OD1yLki0NFQzKM7:TR?= M{Tab3NCVkeHUh?=
KARPAS-45 Mkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C5[GlEPTB;MD64OFI3OyEQvF2= NYTnbGZUW0GQR1XS
TGW MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwOEW4OlMh|ryP MkPHV2FPT0WU
CHP-126 M4K4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm4TmRKSzVyPUCuPFU6PTdizszN NX7IXo8xW0GQR1XS
MOLT-16 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPQ[4lTUUN3ME2wMlg4PTh7IN88US=> M4i5U3NCVkeHUh?=
LB771-HNC M2nNTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjkWXJTUUN3ME2wMlg6PzV5IN88US=> MlS1V2FPT0WU
NALM-6 M3W0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HmdGlEPTB;MD65NFc{QSEQvF2= MnPvV2FPT0WU
GCIY NUXJPFlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3W[29PUUN3ME2wMlk2PTJ4IN88US=> MnP1V2FPT0WU
IST-MES1 NHTHcIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLGZ3ZqUUN3ME2wMlk5QDJ2IN88US=> M{LvR3NCVkeHUh?=
LB2241-RCC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;CbFhKSzVyPUCuPVg5PCEQvF2= NX3yc4h[W0GQR1XS
BL-70 NES0bWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[1S2lEPTB;MD65PVU{PSEQvF2= NXzkNHpWW0GQR1XS
NB17 M1rrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXz[nlKSzVyPUGuNFA3OzlizszN Ml7DV2FPT0WU
LXF-289 NVj4eVNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ziPWlEPTB;MT6wN|A4PiEQvF2= NIfoO45USU6JRWK=
TK10 NFTpR3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLWSW5KSzVyPUGuNFUxPjNizszN M{LFbXNCVkeHUh?=
K5 MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLJTWM2OD1zLkC2Nlc1KM7:TR?= NU\pclU6W0GQR1XS
NCI-H716 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm5TWM2OD1zLkC3NlU6KM7:TR?= MXzTRW5ITVJ?
HCE-T MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nqT2lEPTB;MT6wPFgyQSEQvF2= NEP4Rm5USU6JRWK=
GI-1 MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPpZmw4UUN3ME2xMlA6Pzl6IN88US=> MV3TRW5ITVJ?
KARPAS-422 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHyXopuUUN3ME2xMlExODJ{IN88US=> MoDaV2FPT0WU
TE-9 NV3YZWJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;NXJNlUUN3ME2xMlEyOzJ6IN88US=> M3LTNXNCVkeHUh?=
SF126 NWfsRWdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVGwb|ZqUUN3ME2xMlEyPTZ6IN88US=> Mne2V2FPT0WU
BB30-HNC NGjobXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHxTWM2OD1zLkGzNVEzKM7:TR?= MoHkV2FPT0WU
NCI-H1304 NFfHT|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFwMUOzN|gh|ryP MYDTRW5ITVJ?
HEL M3PU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFwMUS4PVUh|ryP M{jn[nNCVkeHUh?=
HAL-01 M1jMemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTFwMUWyPFMh|ryP NEnxOZJUSU6JRWK=
SK-LMS-1 NUHwVYhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYmxdHdTUUN3ME2xMlE2QTd2IN88US=> MVnTRW5ITVJ?
SW954 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q0TmlEPTB;MT6xPVU3PyEQvF2= MljZV2FPT0WU
D-283MED MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwMkKzO|kh|ryP M1XNVXNCVkeHUh?=
NCI-H1882 NIj1b4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTFwMkO4PUDPxE1? MUjTRW5ITVJ?
GI-ME-N M1PpbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLGe5c2UUN3ME2xMlI2OjB6IN88US=> MV;TRW5ITVJ?
SK-PN-DW Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\wPGlEPTB;MT6yOlM1QCEQvF2= NEDGTWRUSU6JRWK=
C2BBe1 M4rzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILBU4dKSzVyPUGuNlkyOTdizszN NUXud2k6W0GQR1XS
A704 M3SwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHkWHZKSzVyPUGuN|I3QDlizszN MoHvV2FPT0WU
KALS-1 NYfLSXNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjtTZQ6UUN3ME2xMlM1ODhizszN MYDTRW5ITVJ?
ETK-1 NFHYXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFwM{S0PFkh|ryP NWLqbXJtW0GQR1XS
LB647-SCLC NFTlcphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ryW2lEPTB;MT6zOFk5PiEQvF2= NITBPItUSU6JRWK=
OCUB-M MnH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTFwM{[xOFMh|ryP NWO1bmxEW0GQR1XS
NCI-H720 M3zQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\Jb2tKSzVyPUGuN|Y{PzhizszN NYnPSlVxW0GQR1XS
NB13 MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTFwM{eyPVMh|ryP NXzTZXF6W0GQR1XS
GR-ST MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XpRmlEPTB;MT6zPFc2PyEQvF2= NWqzfpF1W0GQR1XS
DU-4475 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTFwNEW4OVMh|ryP MYLTRW5ITVJ?
HCC2157 NX\1[3EzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmraTWM2OD1zLkS2OlU6KM7:TR?= NHL2eFBUSU6JRWK=
RKO MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TuWmlEPTB;MT60PVkzOiEQvF2= NGTndXVUSU6JRWK=
LS-123 MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPlbJZKSzVyPUGuOVE2QTRizszN NGnBWGxUSU6JRWK=
NCI-H69 NFSyZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYThOnFRUUN3ME2xMlU2QDFzIN88US=> NHviR5dUSU6JRWK=
SW962 NF\LTVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTFwNU[xN{DPxE1? NH:3fHRUSU6JRWK=
PF-382 Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoKyTWM2OD1zLkW2PVYh|ryP NWLsTXhSW0GQR1XS
A101D M1;QdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlm1TWM2OD1zLkW3NVE{KM7:TR?= MkLyV2FPT0WU
NB10 NVH6U5ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTFwNUezPVIh|ryP M1GwU3NCVkeHUh?=
NB5 NELBUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1v3TWlEPTB;MT61PFQ4PiEQvF2= MY\TRW5ITVJ?
HCE-4 NF;iVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzyTWM2OD1zLk[wPFUh|ryP MXfTRW5ITVJ?
HT-144 MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDXb5pUUUN3ME2xMlY{OTlizszN NXHGd3V1W0GQR1XS
NCI-H524 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDiTWM2OD1zLk[0N|A4KM7:TR?= NGPqVlhUSU6JRWK=
NKM-1 MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXucJFXUUN3ME2xMlY5PjZizszN NFjMdZFUSU6JRWK=
KURAMOCHI NInVZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\pdFJHUUN3ME2xMlY6PTd|IN88US=> MnjhV2FPT0WU
NCI-H187 NG\yUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnqwTWM2OD1zLkewNFM3KM7:TR?= Ml25V2FPT0WU
U-266 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TEVmlEPTB;MT63N|g1OiEQvF2= MVfTRW5ITVJ?
BL-41 NV75cWh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXrbGt[UUN3ME2xMlc3Ojd{IN88US=> NEj0ZlZUSU6JRWK=
SK-N-DZ NFTKUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\CTWM2OD1zLke4N|A6KM7:TR?= MlLZV2FPT0WU
Daudi M{Lvc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;MTWM2OD1zLke4PVY4KM7:TR?= MomxV2FPT0WU
CPC-N MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrIOm1KSzVyPUGuPFUxQTZizszN MkPXV2FPT0WU
EM-2 MlTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnXeJhqUUN3ME2xMlg2OSEQvF2= MlWyV2FPT0WU
HCC1187 M2LlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jBOmlEPTB;MT64OlI1OSEQvF2= M{DZRnNCVkeHUh?=
LP-1 M4rzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfrXVBFUUN3ME2xMlg4OTR|IN88US=> M3K2T3NCVkeHUh?=
CAS-1 M2my[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTFwOUiyPVkh|ryP NXTmVZJUW0GQR1XS
NB7 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJwMEC1OVUh|ryP MYnTRW5ITVJ?
VA-ES-BJ NETaUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv5cplKUUN3ME2yMlAyPTF|IN88US=> Mn3XV2FPT0WU
SNU-C2B M2j2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3m1VWlEPTB;Mj6wN|M2OSEQvF2= NUjjW|M4W0GQR1XS
LOXIMVI NFHKc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\NfGlEPTB;Mj6wOlc5PiEQvF2= NYTLPYNHW0GQR1XS
NCI-H1581 NFHZVWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknrTWM2OD1{LkGxOVU6KM7:TR?= Mk\mV2FPT0WU
IST-SL2 M{fXXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTJwMUK0OFUh|ryP NUfrTpFSW0GQR1XS
NOMO-1 NUXobXNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HYSWlEPTB;Mj6xO|Y5OyEQvF2= MomyV2FPT0WU
TE-6 NWGyXVlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJwMUmwOUDPxE1? NGfHTWdUSU6JRWK=
NCI-H526 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEm2WZZKSzVyPUKuNVkyPDFizszN MVPTRW5ITVJ?
MSTO-211H MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\rTWM2OD1{LkKwNFQyKM7:TR?= MoPrV2FPT0WU
LS-513 NWPs[4tNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTJwMkKyOlkh|ryP M1PX[nNCVkeHUh?=
NCI-SNU-1 NYHWRYM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTJwM{OyOVYh|ryP MXTTRW5ITVJ?
BB65-RCC NX3HSW14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TIeGlEPTB;Mj6zO|Q6OyEQvF2= NUHvPYh1W0GQR1XS
GT3TKB NWXObYxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TFb2lEPTB;Mj6zPVk4OiEQvF2= MUTTRW5ITVJ?
OS-RC-2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7xZYNxUUN3ME2yMlQzOzRzIN88US=> M{fKcnNCVkeHUh?=
NCI-H2126 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;DbFdKSzVyPUKuOFM3PzRizszN NGfJSlRUSU6JRWK=
SK-UT-1 NHvVdo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HNTmlEPTB;Mj60O|Q3PyEQvF2= MkfkV2FPT0WU
DMS-114 M13sOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPKZ3pKSzVyPUKuOlE2OjRizszN M33rWHNCVkeHUh?=
ONS-76 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkThTWM2OD1{Lk[zOlQyKM7:TR?= M1S0[nNCVkeHUh?=
8-MG-BA MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJwNkW0NVQh|ryP MoPZV2FPT0WU
BOKU NGHyV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3NTWM2OD1{LkeyO|Y1KM7:TR?= NHTWVXNUSU6JRWK=
LAMA-84 MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETLUIZKSzVyPUKuO|k6OTJizszN M{XmeHNCVkeHUh?=
ES1 Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP4TWM2OD1{LkixPFA1KM7:TR?= NH\Kb3pUSU6JRWK=
NCI-H1395 NGT6SZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULOb4tKUUN3ME2yMlgzODF{IN88US=> MYXTRW5ITVJ?
A388 NYmwTYxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJwOU[xO{DPxE1? NGW2NFlUSU6JRWK=
NCCIT NFTvW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIm5fo9KSzVyPUOuNFg5PjJizszN NV3lSIRHW0GQR1XS
HD-MY-Z MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnoXGNRUUN3ME2zMlE{OjB|IN88US=> MkT1V2FPT0WU
NCI-H510A M4DqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrVWlhUUUN3ME2zMlE5QTR|IN88US=> NYm5PYo6W0GQR1XS
NCI-N87 MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\5bnI4UUN3ME2zMlIxODJizszN MWXTRW5ITVJ?
SCLC-21H NFXNVW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTNwMk[4OVkh|ryP M3;GRXNCVkeHUh?=
SH-4 M2LHRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L0Z2lEPTB;Mz6yPFc6PyEQvF2= NEjwT2pUSU6JRWK=
QIMR-WIL NFrFZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXCTWM2OD1|LkOyPFQ6KM7:TR?= M3XZWXNCVkeHUh?=
KM12 NIfaVmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTNwM{O1OFQh|ryP M2S4b3NCVkeHUh?=
ST486 NXvnVYpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;qT2lEPTB;Mz61N|g5OyEQvF2= M3L0fnNCVkeHUh?=
HC-1 NVezNmZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\hTWM2OD1|Lk[yNFI5KM7:TR?= MkDRV2FPT0WU
BV-173 NGWxXJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHMRphKSzVyPUOuOlQxQDhizszN M2XDXnNCVkeHUh?=
EW-24 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n1VWlEPTB;Mz62OlQ{PCEQvF2= NIru[WxUSU6JRWK=
LU-65 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TtZ2lEPTB;Mz62PFcyKM7:TR?= MXLTRW5ITVJ?
ECC4 NEG5NZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTNwN{e1OkDPxE1? NEn2O2pUSU6JRWK=
ARH-77 M1vC[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTRwMUGwOlch|ryP NIfhdIJUSU6JRWK=
BC-3 NIC1cJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHUOFduUUN3ME20MlE{ODZ6IN88US=> MWPTRW5ITVJ?
SNB75 NY\kO2RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXuTWM2OD12LkK2NVkh|ryP NVzY[4dkW0GQR1XS
MEG-01 M{fXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r6TmlEPTB;ND6yO|QyQSEQvF2= M4L3UnNCVkeHUh?=
NCI-H1417 M1;qXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfmXJprUUN3ME20MlI5PDR|IN88US=> NFj6eIdUSU6JRWK=
MDA-MB-134-VI NUjPT5NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljFTWM2OD12LkOwOlAyKM7:TR?= MVHTRW5ITVJ?
Becker NWHacVZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPwTWM2OD12LkS3N|M3KM7:TR?= NX\rVYdtW0GQR1XS
DMS-153 M2fldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTRwNk[0O|Uh|ryP MYnTRW5ITVJ?
TGBC1TKB M33jXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzYOmZKSzVyPUSuOlg2OTVizszN MV;TRW5ITVJ?
EW-3 NXTuO4ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjx[mdKSzVyPUSuO|YzPDhizszN MYjTRW5ITVJ?
KE-37 NYHE[2lHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjmb2l5UUN3ME20Mlg3OTl4IN88US=> MUPTRW5ITVJ?
NCI-H23 NE\adG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7mWJg5UUN3ME20Mlg4OjJ5IN88US=> M1;l[XNCVkeHUh?=
MC116 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfsdJdKSzVyPUSuPVQyOjZizszN MmKyV2FPT0WU
NH-12 NED5d|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfUTplXUUN3ME20Mlk3PDN7IN88US=> NGTJT4JUSU6JRWK=
CTB-1 M2rFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfEfVJqUUN3ME20Mlk4PzJzIN88US=> M1vKU3NCVkeHUh?=
KM-H2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTVwMEWzNlMh|ryP M3vie3NCVkeHUh?=
MOLT-4 Mk\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInwdZJKSzVyPUWuNVE5OyEQvF2= NWDnbmhMW0GQR1XS
NCI-H2141 MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLnfmVkUUN3ME21MlE1OjZ6IN88US=> M2fYR3NCVkeHUh?=
EB-3 NV7XSplxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTlcY9lUUN3ME21MlE4PTB2IN88US=> NIDo[4NUSU6JRWK=
NCI-H1522 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fxW2lEPTB;NT6yOlMzOiEQvF2= NFrlSotUSU6JRWK=
MRK-nu-1 Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3YNGM4UUN3ME21MlQ{PjN|IN88US=> MWfTRW5ITVJ?
no-11 NFPjc5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rYVGlEPTB;NT60O|A5PyEQvF2= M1nxfXNCVkeHUh?=
CESS MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPITWM2OD13LkW4NFM1KM7:TR?= MXfTRW5ITVJ?
KMOE-2 NFrk[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTVwNUi2OVkh|ryP MXrTRW5ITVJ?
REH NITMNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjBTIJkUUN3ME22MlI2PjF6IN88US=> MV3TRW5ITVJ?
KU812 NXXm[41kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPlR5J2UUN3ME22MlQzPzlzIN88US=> MX\TRW5ITVJ?
SK-N-FI M4TD[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfqU4lqUUN3ME22MlYxPjd2IN88US=> MVTTRW5ITVJ?
MMAC-SF M1uzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1u0cmlEPTB;Nz6wOlQ6OiEQvF2= NF;BUGhUSU6JRWK=
RCC10RGB MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTYOWRPUUN3ME23MlIzQTd5IN88US=> NYi2UJJNW0GQR1XS
NCI-H322M M2fC[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD2WnNKSzVyPUeuN|M{OzVizszN MVzTRW5ITVJ?
NB6 M{TWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHmPHRIUUN3ME23MlU1QDl7IN88US=> MkPiV2FPT0WU
MN-60 NV;uW4xtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvnUY5KSzVyPUeuOlkzOTVizszN MUjTRW5ITVJ?
NCI-H1092 M3TqPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDlTWM2OD16LkCxO|M1KM7:TR?= MYjTRW5ITVJ?
EKVX M2f6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPIXoJKSzVyPUiuOFcxPjZizszN Mk[4V2FPT0WU
D-263MG MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTyboZxUUN3ME24MlU2Ozl4IN88US=> NVTDUoJJW0GQR1XS
NCI-H209 NXTVcFFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRThwNkSwNFYh|ryP M3zsNXNCVkeHUh?=
IST-SL1 NFTvdXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mli1TWM2OD16Lki5PFkzKM7:TR?= NUD3TphnW0GQR1XS
ACN NUT3WnZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzPVlU1UUN3ME25MlE6OTV5IN88US=> M1PjdXNCVkeHUh?=
MHH-PREB-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrCcpBKSzVyPUmuNlEzOTlizszN NUjP[5A3W0GQR1XS
EW-11 M37BNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LFNGlEPTB;OT62OVM6PiEQvF2= Mlf2V2FPT0WU
KASUMI-1 NFPzdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nSV2lEPTB;OT63PFc4KM7:TR?= MmHYV2FPT0WU
KINGS-1 NIK5SXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\BU2hnUUN3ME2xNE4zOzR5IN88US=> NIjucYhUSU6JRWK=
EVSA-T M33wNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTFyLkOxPVIh|ryP Mo\BV2FPT0WU
DSH1 NIrHXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\HTWM2OD1zMD6zPVczKM7:TR?= MV\TRW5ITVJ?
COLO-824 Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTFyLki2Olkh|ryP NFTI[VZUSU6JRWK=
K052 NYjWV2RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrxbWNKSzVyPUGwMlk{OjJizszN M2rD[HNCVkeHUh?=
SK-MEL-2 NGrZe5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFyLkm5N|kh|ryP Mm\zV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo After 4 weeks of treatment with TAE684 at 3 and 10 mg/kg, there is a significant delay in lymphoma development and 100- to 1,000-fold reduction in luminescence signal, without any signs of compound- or disease-related toxicity in Karpas-299 lymphoma model. TAE684 treatment also induces disease regression in established Karpas-299 lymphomas and down-regulates CD30 expression. [1] TAE684 also shows impressive antitumor activity against H3122 CR xenograft tumors. [2] Furthermore, treatment with TAE684 improves the rough eye phenotype of both ALK mutants, especially that seen with ALKR1275Q, whereas Crizotinib has little effect on either phenotype. [3]

Protocol

Kinase Assay:[1]
+ Expand

In vitro Enzyme Assays.:

All in vitro enzyme assays are done at Upstate Biotechnology with the exception of InsR and IGF-1R. To determine the IC50 of TAE684 against InsR and IGF-1R a homogeneous time-resolved fluorescence assay is performed. ATP (10 mM) and 20 mg/ml biotinylated PolyEY (Glu, Tyr 4:1) are combined with 50 nL of serial dilutions of TAE684 (10-500 nM) and 4 ng of InsR enzyme in the presence of the kinase reaction buffer (20 mM Tris譎Cl, pH 7.5/10 mM MgCl2/3 mM MnCl2/1 mM DTT/10 mM NaVO4/0.1 mg/ml of BSA). Assays are incubated for 1 hour at ambient temperature. Reactions are terminated by adding 10 mL of the detection solution containing 50 mM EDTA, 500 mM KF, 0.5 mg/ml of BSA, 5 mg/mL Eu3+ cryptate-labeled anti-phosphotyrosine antibody Mab PT66-K, and 5 mg/mL Streptavidin-XLent. The reaction is incubated for half an hour, and fluorescence signals are read on Analyst GT.
Cell Research:[1]
+ Expand
  • Cell lines: Luciferase-expressing Karpas-299, SU-DHL-1, and Ba/F3 cells and transformed Ba/F3 stably expressing NPM-ALK, Bcr-Abl, or TEL-kinase fusion constructs.
  • Concentrations: 1 nM-10 μM
  • Incubation Time: 2–3 days
  • Method: Cells are seeded in 384-well plates (2.5×104 cells per well) and incubated with serial dilutions of TAE684 or DMSO for 2–3 days. Luciferase expression is used as a measure of cell proliferation/survival and is evaluated with the Bright-Glo Luciferase Assay System. IC50 values are generated by using XLFit software.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Karpas-299 xenografts are established in 4- to 6-week old female Fox Chase SCIDBeige mice.
  • Formulation: Resuspended in 10% 1-methyl-2-pyrrolidinone/90% polyethylene glycol 300 solution
  • Dosages: 1, 3, and 10 mg/kg
  • Administration: Once daily by oral gavage for 3 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 3 mg/mL (4.88 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol, pH 4
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 614.2
Formula

C30H40ClN7O3S

CAS No. 761439-42-3
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

ALK Signaling Pathway Map

ALK Inhibitors with Unique Features

Related ALK Products

Tags: buy TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) supplier | purchase TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) cost | TAE684 (NVP-TAE684) manufacturer | order TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID